MedTrace Logo

Itopride in Functional Dyspepsia:a Dose Finding Study

NCT00272103 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2006-05-04

No results posted yet for this study

Summary

This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia.

The study will test in patients with functional dyspepsia the hypothesis that itopride is superior to placebo with regard to the improvement of symptoms.

Conditions

  • Functional Dyspepsia

Interventions

DRUG

Itopride (drug)

Sponsors & Collaborators

  • Knoll Pharmaceuticals, Germany (now Abbott)

    collaborator UNKNOWN

  • University Hospital, Essen

    collaborator OTHER

  • Royal Adelaide Hospital

    lead OTHER

Principal Investigators

  • Gerald J Holtmann, MD · Royal Adelaide Hospital, University of Adelaide

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Completion
2002-01-31

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272103 on ClinicalTrials.gov